Ibroscan and Ultrasonography in the Evaluation of Hepatic Steatosis and Fibrosis Amongst Candidates for Bariatric Surgery

Document Type : Original Article(s)

Authors

1 Isfahan Minimally Invasive Surgery and Obesity Research Center, Department of Surgery, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Radiology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

10.48305/jims.v43.i826.0935

Abstract

Background: The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. NAFLD is closely associated with obesity and is more common in candidates for bariatric surgery. This study compared the results of ultrasonography, transient elastography (FibroScan), and liver biopsy in assessing hepatic steatosis and fibrosis severity.
Methods: This cross-sectional study was conducted at Al-Zahra Hospital, Isfahan, Iran, from 2018 to 2020. Participants in the study were candidates for bariatric surgery with a body mass index (BMI) of more than 40. All patients underwent preoperative liver assessment via ultrasonography, FibroScan, and liver biopsy. The results of the different methods were compared in terms of hepatic steatosis grade and hepatic fibrosis stage.
Findings: 36 patients with a BMI of more than 40 who were candidates for bariatric surgery were included in the study; 69.4% of whom (n = 25) were female. The average BMI for men was calculated as 47.21 ± 5.72 (SD) and 44.54 ± 3.03 for women. No significant difference was observed between FibroScan and liver biopsy results regarding the severity of liver fibrosis (P = 0.83). There was a significant difference between steatosis grade based on biopsy and ultrasound findings (P < 0.001). Additionally, no significant difference was observed between hepatic steatosis grade and fibrosis stage based on liver biopsy (P = 1.00).
Conclusion: We have shown that the results of FibroScan are statistically similar to those of liver biopsy and this non-invasive method is a reliable alternative to biopsy among patients with morbid obesity. We also showed that the results of ultrasound in patients with a BMI greater than 40 are not accurate and reliable when compared to biopsy.

Highlights

Masoud Sayyadi shahraki: Google Scholar

Mohsen Mahmoudieh: Google Scholar

Mitra Heidarpour: Google Scholar

Keywords

Main Subjects

References

  1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—meta‐analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016; 64(1): 73-84.
  2. Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol 2002; 9(1): 37-51.
  3. Rashid M, Roberts EA. Nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2000; 30(1): 48-53.
  4. Newton JL. Systemic symptoms in non-alcoholic fatty liver disease. Dig Dis 2010; 28(1): 214-9.
  5. Afdhal NH. Biopsy or biomarkers: is there a gold standard for diagnosis of liver fibrosis? Clin Chem 2004; 50(8): 1299-300.
  6. De Ledinghen V, Vergniol J. Transient elastography (fibroscan). Gastroenterol Clin Biol 2008; 32(6): 58-67.
  7. Yoneda M, Fujita K, Inamori M, Nakajima A, Tamano M, Hiraishi H. Transient elastography in patients with non-alcoholic fatty liver disease (NAFLD). Gut 2007; 56(9): 1330-1.
  8. Gomercić M, Duvnjak M, Barsić N. Ultrasonography in the diagnosis of nonalcoholic fatty liver disease. Acta Med Croatica 2009; 63(Suppl 3): 1-3.
  9. Hernaez R, Lazo M, Bonekamp S, Kamel I, Brancati FL, Guallar E, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta‐analysis. Hepatology 2011; 54(3): 1082-90.
  10. Mottin CC, Moretto M, Padoin AV, Swarowsky AM, Toneto MG, Glock L, et al. The role of ultrasound in the diagnosis of hepatic steatosis in morbidly obese patients. Obes Surg 2004; 14(5): 635-7.
  11. Younossi ZM, Stepanova M, Afendy M, Fang Y, Younossi Y, Mir H, et al. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin Gastroenterol Hepatol 2011; 9(6): 524-30. e1.
Journal of Isfahan Medical School
Volume 43, Issue 826
2nd Week, October
September and October 2025
Pages 935-940

Files

History

  • Receive Date: 20 April 2025
  • Accept Date: 12 July 2025

Share

How to cite

Statistics